checkAd

     165  0 Kommentare Cara Therapeutics Announces Approval of KORSUVA IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients - Seite 3

    MEDIA CONTACT:
    Annie Spinetta
    6 Degrees
    973-768-2170
    aspinetta@6degreespr.com

    Lesen Sie auch

    INVESTOR CONTACT:
    Iris Francesconi, Ph.D.
    Cara Therapeutics
    203-406-3700
    investor@caratherapeutics.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Cara Therapeutics Announces Approval of KORSUVA IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients - Seite 3 Approval triggers $1.5 million milestone payment to CaraSTAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives …